Pamisel Nears Completion of Phase 1 Clinical Trial for Chronic Kidney Disease Treatment

[Asia Economy Reporter Hyungsoo Park] Pharmicell announced on the 18th that the Phase 1 clinical trial of the chronic kidney disease treatment ‘Cellgram-CKD’ is in its final stages.

Cellgram-CKD is an allogeneic stem cell therapy developed by selecting and culturing stem cells with excellent therapeutic efficacy from the bone marrow of healthy donors for the treatment of chronic kidney disease. The Phase 1 clinical trial, approved last July for 10 patients, is being conducted at Seoul Asan Medical Center. So far, 9 patients have been recruited.

A Pharmicell official explained, "The clinical trial of Cellgram-CKD targets chronic kidney disease patients aged 19 to under 80," adding, "Unlike existing autologous stem cell therapies, there is no need for bone marrow extraction from the patient, reducing the burden on patients."

He continued, "The Phase 1 trial requires a one-year follow-up period after administration of the treatment," and added, "No patients have shown severe adverse reactions so far, so we expect good results."

Pharmicell aims to enter Phase 2 clinical trials next year.

This content was produced with the assistance of AI translation services.